Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Short-term Investments: 2012-2018

Historic Short-term Investments for Cumberland Pharmaceuticals (CPIX) over the last 7 years, with Dec 2018 value amounting to $8.3 million.

  • Cumberland Pharmaceuticals' Short-term Investments rose 77.44% to $8.3 million in Q4 2018 from the same period last year, while for Dec 2018 it was $8.3 million, marking a year-over-year increase of 77.44%. This contributed to the annual value of $8.3 million for FY2018, which is 77.44% up from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported Short-term Investments of $8.3 million as of FY2018, which was up 77.44% from $4.7 million recorded in FY2017.
  • Over the past 5 years, Cumberland Pharmaceuticals' Short-term Investments peaked at $15.6 million during FY2016, and registered a low of $4.7 million during FY2017.
  • Its 3-year average for Short-term Investments is $9.5 million, with a median of $8.3 million in 2018.
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Short-term Investments crashed by 70.09% in 2017 and then spiked by 77.44% in 2018.
  • Yearly analysis of 5 years shows Cumberland Pharmaceuticals' Short-term Investments stood at $14.8 million in 2014, then decreased by 1.87% to $14.6 million in 2015, then rose by 7.26% to $15.6 million in 2016, then tumbled by 70.09% to $4.7 million in 2017, then spiked by 77.44% to $8.3 million in 2018.